5 Jun 2017 18:20
5 June 2017
Motif Bio plc("Motif Bio" or the "Company")
Posting of Shareholder Circular
5 June 2017: Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, confirms that, further to the announcement on 2 June 2017, a circular has been published and posted to shareholders today in relation to the proposed Placing of 66,666,667 New Ordinary Shares at 30 pence per share. The circular contains the notice convening the General Meeting to be held at the offices of DLA Piper LLP at 3 Noble Street, London, EC2V 7EE at 2.00 p.m. on 22 June 2017.
A copy of the Circular will shortly be available on the Company's website (www.motifbio.com).
For further details please contact:
Motif Bio plc | info@motifbio.com | ||
Graham Lumsden (Chief Executive Officer) | |||
Rob Dickey (Chief Financial Officer) | |||
Peel Hunt LLP (NOMAD & BOOKRUNNER) | + 44 (0)20 7418 8900 | ||
Dr. Christopher Golden | |||
Oliver Jackson | |||
Rory James-Duff | |||
Northland Capital Partners Limited (CO-LEAD MANAGER) | +44 (0)203 861 6625 | ||
Patrick Claridge/ David Hignell | |||
John Howes/ Rob Rees (Broking) | |||
Walbrook PR Ltd. (FINANCIAL PR & IR) | +44 (0) 20 7933 8780 or motifbio@walbrookpr.com | ||
Paul McManus | Mob: +44 (0)7980 541 893 | ||
Mike Wort | Mob: +44 (0)7900 608 002 | ||
MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 | ||
Raimund Gabriel | |||
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.